KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenon Pharmaceuticals (XENE) Enterprise Value: 2013-2025

Historic Enterprise Value for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to $2.2 billion.

  • Xenon Pharmaceuticals' Enterprise Value fell 6.27% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$582.4 million, marking a year-over-year decrease of 316.03%. This contributed to the annual value of $1.7 billion for FY2024, which is 26.33% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Enterprise Value of $2.2 billion as of Q3 2025, which was up 53.20% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Enterprise Value ranged from a high of $2.5 billion in Q1 2024 and a low of $366.3 million during Q1 2021.
  • Its 3-year average for Enterprise Value is $2.0 billion, with a median of $2.0 billion in 2025.
  • In the last 5 years, Xenon Pharmaceuticals' Enterprise Value soared by 324.95% in 2022 and then slumped by 35.85% in 2025.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Enterprise Value stood at $1.1 billion in 2021, then skyrocketed by 76.82% to $1.9 billion in 2022, then climbed by 26.77% to $2.4 billion in 2023, then declined by 26.33% to $1.7 billion in 2024, then decreased by 6.27% to $2.2 billion in 2025.
  • Its last three reported values are $2.2 billion in Q3 2025, $1.4 billion for Q2 2025, and $2.0 billion during Q1 2025.